Contraceptive Drugs and Devices Market Report 2026

The contraceptive drugs and devices market size has grown strongly in recent years. It will grow from $26.98 billion in 2025 to $28.9 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to government-led family planning initiatives, increased awareness of reproductive health, rising urbanization and education levels, wider availability of oral contraceptives, public health campaigns for birth control.

The contraceptive drugs and devices market size is expected to see strong growth in the next few years. It will grow to $38.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to growth in digital health integration, rising demand for non-invasive contraceptive methods, expansion of telehealth-based prescriptions, increasing focus on male contraception research, supportive reproductive health policies. Major trends in the forecast period include rising adoption of long-acting reversible contraceptives, increasing use of hormonal combination therapies, growing demand for female-centric contraceptive solutions, expansion of over-the-counter contraceptive products, increasing acceptance of digital contraceptive platforms.

The increasing number of government initiatives focused on reproductive health is expected to drive the growth of the contraceptive drugs and devices market in the coming years. These initiatives promote reproductive health through awareness campaigns, funding, and access to essential services. The rise in such initiatives is largely due to the growing recognition of the importance of addressing maternal health, family planning, and access to healthcare, which are vital for societal well-being and development. Government programs for contraceptive drugs and devices aim to improve access to affordable and effective family planning methods, enabling individuals to make informed reproductive health decisions. For example, in November 2024, according to the Australian Government Department of Foreign Affairs and Trade, Australia allocated $56.8 million to a new initiative promoting sexual and reproductive health and rights in Southeast Asia. Therefore, the growing number of government initiatives on reproductive health is driving the expansion of the contraceptive drugs and devices market.

Major companies in the contraceptive drugs and devices market are focusing on developing innovative products, such as contraceptive vaginal rings, to improve user convenience and expand long-acting birth control options. A contraceptive vaginal ring is a flexible device inserted into the vagina that steadily releases hormones to prevent pregnancy by suppressing ovulation. For example, in October 2023, Xiromed LLC, a US-based pharmaceutical company, launched EnilloRing, a soft, flexible contraceptive vaginal ring designed for vaginal insertion. It gradually delivers a combination of etonogestrel (a progestin) and ethinyl estradiol (an estrogen) over three weeks to prevent ovulation. As a bioequivalent generic to NuvaRing, it provides women with a convenient, discreet, and cost-effective monthly birth control option, eliminating the need for daily dosing while maintaining the same safety, efficacy, and tolerability as the branded version.

In March 2024, Insud Pharma SL, a Spain-based pharmaceutical company, acquired Viatris Inc.'s women's healthcare business for an undisclosed amount. Through this acquisition, Insud Pharma strengthens its presence in emerging markets by gaining two manufacturing facilities in India and enhancing its capacity to supply oral contraceptives to global public health organizations. Viatris Inc. is a US-based pharmaceutical and healthcare company specializing in oral and injectable contraceptives.

Major companies operating in the contraceptive drugs and devices market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co Inc., Bayer AG, Viatris Inc., Teva Pharmaceuticals Ltd, Lupin Limited, CooperSurgical Inc., Mithra Pharmaceuticals, DKT International, Fuji Latex Co Ltd, Agile Therapeutics Inc., Cupid Limited, Veru Inc., Eskag Pharma Pvt. Ltd., Biosante Pharmaceuticals Inc., HLL Lifecare Limited, Afaxys Inc., The Female Health Company (FC2), Mayer Laboratories Inc., Daré Bioscience Inc.

North America was the largest region in the contraceptive drugs and devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the contraceptive drugs and devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the contraceptive drugs and devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the contraceptive drugs and devices market by increasing the cost of imported active pharmaceutical ingredients, medical-grade polymers, and device components used in contraceptive formulations and products. These impacts have been most pronounced in hormonal contraceptive drugs and intrauterine device segments, particularly in North America and Europe where global sourcing is common. Asia-Pacific manufacturers have faced pricing pressure due to reliance on imported raw materials. However, tariffs have encouraged localized manufacturing and domestic production of contraceptive drugs and devices.

The contraceptive drugs and devices market research report is one of a series of new reports that provides contraceptive drugs and devices market statistics, including contraceptive drugs and devices industry global market size, regional shares, competitors with a contraceptive drugs and devices market share, detailed contraceptive drugs and devices market segments, market trends and opportunities, and any further data you may need to thrive in the contraceptive drugs and devices industry. This contraceptive drugs and devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Contraceptive drugs and devices are medical products designed to prevent pregnancy through various methods. Contraceptive drugs typically contain synthetic hormones that inhibit ovulation, thicken cervical mucus, or alter the uterine lining. Devices include physical barriers that block sperm and intrauterine systems that prevent fertilization or implantation.

The main products in this category are contraceptive drugs and contraceptive devices. Contraceptive drugs work by interfering with ovulation, fertilization, or implantation. Technologies include traditional methods, digital contraceptive apps, wearable devices, and long-acting reversible contraceptives (LARCs). Distribution channels include hospital pharmacies, retail pharmacies, clinics, online platforms, public channels, non-governmental organizations, and others, serving end users such as males and females.

The contraceptive drugs and devices market consists of sales of hormonal pills, emergency contraceptives, contraceptive implants, intrauterine devices (IUDs), condoms, patches, and vaginal rings. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.